94 related articles for article (PubMed ID: 7755392)
21. Characteristic antitumor activity of cytarabine ocfosfate against human colorectal adenocarcinoma xenografts in nude mice.
Koga K; Iizuka E; Sato A; Ekimoto H; Okada M
Cancer Chemother Pharmacol; 1995; 36(6):459-62. PubMed ID: 7554036
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with higher-risk myelodysplastic syndromes compared to that in elderly acute myeloid leukemia patients.
Horikoshi A; Iriyama N; Hirabayashi Y; Kodaira H; Matsukawa Y; Uchino Y; Takahashi H; Hatta Y; Takeuchi J; Kobayashi S; Miura K
Chemotherapy; 2013; 59(2):152-8. PubMed ID: 24080768
[TBL] [Abstract][Full Text] [Related]
23. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
[TBL] [Abstract][Full Text] [Related]
24. [Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) on hematological malignancies].
Tatsumi N; Yamada K; Ohshima T; Nakamura T; Ohno R; Masaoka T; Kimura I; Kimura K
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2387-95. PubMed ID: 2260876
[TBL] [Abstract][Full Text] [Related]
25. Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia.
Kalambokis G; Stefanou D; Arkoumani E; Kitsanou M; Bourantas K; V Tsianos E
Eur J Haematol; 2004 Jul; 73(1):67-70. PubMed ID: 15182341
[TBL] [Abstract][Full Text] [Related]
26. Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate.
Arahata M; Shimizu Y; Asakura H; Nakao S
J Hematol Oncol; 2015 Feb; 8():5. PubMed ID: 25652695
[TBL] [Abstract][Full Text] [Related]
27. [Refractory anemia with excess myeloblast in transformation induced remission by combined oral administration of cytarabine ocfosfate and 6-mercaptopurine].
Fukumi S; Mizorogi F; Matsuo A; Sato H; Abe T
Gan To Kagaku Ryoho; 1995 Jun; 22(7):945-8. PubMed ID: 7794001
[TBL] [Abstract][Full Text] [Related]
28. [Successful treatment of acute myelomonocytic leukemia developed from essential thrombocythemia with cytarabine plus etoposide].
Ishii Y; Goto A; Katagiri T; Miyazawa K; Ohyashiki K
Rinsho Ketsueki; 2004 Nov; 45(11):1211-3. PubMed ID: 15609690
[TBL] [Abstract][Full Text] [Related]
29. A severe hepatic disorder with myelodysplastic syndrome, treated with cytarabine ocfosfate, in a dog.
Ide K; Momoi Y; Minegishi M; Sekiguchi M; Konno K; Iwasaki T
Aust Vet J; 2003; 81(1-2):47-9. PubMed ID: 15084010
[TBL] [Abstract][Full Text] [Related]
30. The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients.
Horikoshi A; Takei K; Hosokawa Y; Sawada S
Int J Hematol; 2008 Mar; 87(2):118-125. PubMed ID: 18228114
[TBL] [Abstract][Full Text] [Related]
31. [Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma].
Suto T; Yoshida Y; Sakata Y; Ono T; Yoshida T; Yamada N; Chida N; Oohira H
Gan To Kagaku Ryoho; 1998 Oct; 25(12):1933-8. PubMed ID: 9797816
[TBL] [Abstract][Full Text] [Related]
32. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
[TBL] [Abstract][Full Text] [Related]
33. Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study.
Kühr T; Eisterer W; Apfelbeck U; Linkesch W; Bechter O; Zabernigg A; Geissler K; Barbieri G; Duba C; Gastl G; Thaler J
Leuk Res; 2000 Jul; 24(7):583-7. PubMed ID: 10867132
[TBL] [Abstract][Full Text] [Related]
34. Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone.
Braess J; Kern W; Unterhalt M; Kaufmann CC; Ramsauer B; Schüssler M; Kaeser-Fröhlich A; Hiddemann W; Schleyer E
Ann Hematol; 1996 Oct; 73(4):201-4. PubMed ID: 8890711
[TBL] [Abstract][Full Text] [Related]
35. [Successful treatment of myelodysplastic syndrome with cytarabine ocfosfate].
Arai T; Narimiya S; Hayakawa K; Takaya T; Toshima S; Araki M; Uchida A; Yoshimi N; Shibuya C; Yasuda Y
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1085-8. PubMed ID: 8002627
[No Abstract] [Full Text] [Related]
36. Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon.
Cervantes F; Sureda A; Hernández-Boluda JC; Martino R; Brunet S; Borrego D; Antich JL; Montserrat E
Haematologica; 2001 Dec; 86(12):1281-6. PubMed ID: 11726320
[TBL] [Abstract][Full Text] [Related]
37. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
38. Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.
Mollee P; Arthur C; Hughes T; Januszewicz H; Grigg A; Bradstock K; Wolf M; Gibson J; Schwarer AP; Spencer A; Browett P; Hawkins T; Seldon M; Herrmann R; Watson A; Seymour JF; Martin N; Shina S; Low C; Wright S; Rodwell R; Coulston J; Morton J; Blacklock H; Taylor D; Taylor KM
Ann Oncol; 2004 Dec; 15(12):1810-5. PubMed ID: 15550587
[TBL] [Abstract][Full Text] [Related]
39. Colony growth in cultures from bone marrow and peripheral blood after curative treatment for leukemia and severe aplastic anemia.
Betticher DC; Huxol H; Müller R; Speck B; Nissen C
Exp Hematol; 1993 Nov; 21(12):1517-21. PubMed ID: 8405233
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
